Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion LUNG-3 adjuvant zongertinib vs standard of care in early-stage HER2-mutant NSCLC
jRCT2031250554Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2025
- Modality
- Small Molecules
01
Overview
Randomised trial in non-small cell lung cancer (NSCLC) comparing Adjuvant zongertinib with Standard of care (2 arms). Primary endpoint: Disease-free survival. Started Dec 2025; status: recruiting.
02
Drugs
zongertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031250554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250554.